DeepMed Research

Paromomycin

Generic Name: Paromomycin

Brand Names: Humatin

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₄₅N_₅O_₁₄

CAS Number: 7542-37-2

Unique Ingredient Identifier: 61JJC8N5ZK

Background: An oligosaccharide antibiotic produced by various streptomyces. [PubChem]

Indication: For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.

Associated Conditions: Dientamoeba fragilis infection, Hepatic coma, Acute Intestinal amebiasis, Chronic Intestinal amebiasis

Clinical Trials

Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults

Not Applicable

Recruiting

Conditions: Dientamoeba Fragilis Infection

Interventions: Drug: Paromomycin

First Posted Date: 2025-04-02

Last Posted Date: 2025-04-02

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 60

Registration Number: NCT06907498

Locations: 🇮🇱
Sheba medical center, Ramat Gan, Israel

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Phase 2

Recruiting

Conditions: Primary Visceral Leishmaniasis

Interventions: Drug: sodium stibogluconate
Drug: LXE408
Drug: Paromomycin

First Posted Date: 2023-07-24

Last Posted Date: 2024-11-08

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 52

Registration Number: NCT05957978

Locations: 🇪🇹
University of Gondar, Gondar, Ethiopia

Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

Phase 2

Completed

Conditions: Cutaneous Leishmaniasis, American

Interventions: Drug: Miltefosine and Paromomycin
Drug: paromomycin
Drug: miltefosine

First Posted Date: 2019-02-04

Last Posted Date: 2021-02-02

Lead Sponsor: Fundacion Nacional de Dermatologia

Target Recruit Count: 120

Registration Number: NCT03829917

Locations: 🇧🇴
Hopital, Dermatologico, Jorochito, SC, Bolivia

Oral Antibiotic Prophylaxis in Colorectal Surgery

Conditions: Surgical Site Infection
Anastomotic Leak

Interventions: Drug: Paromomycin Sulfate Powder

First Posted Date: 2018-11-30

Last Posted Date: 2020-01-07

Lead Sponsor: University of Leipzig

Target Recruit Count: 100

Registration Number: NCT03759886

Locations: 🇩🇪
Universitätsklinikum Leipzig - AöR, Leipzig, Sachsen, Germany

Short Course Regimens for Treatment of PKDL (Sudan)

Phase 2

Conditions: PKDL - Post-Kala-Azar Dermal Leishmanioid

Interventions: Drug: Paromomycin
Drug: Ambisome
Drug: Miltefosine

First Posted Date: 2018-01-17

Last Posted Date: 2020-01-18

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 110

Registration Number: NCT03399955

Locations: 🇸🇩
Prof. Elhassan Centre for tropical Medicine, Doka, Gedaref, Sudan

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Phase 3

Completed

Conditions: Visceral Leishmaniasis

Interventions: Drug: Miltefosine
Drug: Paromomycin
Drug: Sodium stibogluconate

First Posted Date: 2017-04-26

Last Posted Date: 2024-02-29

Lead Sponsor: Drugs for Neglected Diseases

Target Recruit Count: 439

Registration Number: NCT03129646

Locations: 🇪🇹
Abdurafi MSF Health Center, Ābderafī, Amhara, Ethiopia
🇸🇩
El Hassan Centre for Tropical Medicine, Doka, Gedaref, Sudan
🇰🇪
Kacheliba Hospital, Kapenguria, West Pokot, Kenya

and more 4 locations

Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia

Phase 2

Completed

Conditions: Leishmaniasis, Cutaneous
Leishmania Braziliensis Complex
Leishmaniasis, American
Leishmaniasis; American, Cutaneous

Interventions: Drug: Paromomycin Sulfate
Other: Placebo
Drug: Pentamidine Isethionate

First Posted Date: 2017-03-30

Last Posted Date: 2021-02-02

Lead Sponsor: Fundacion Nacional de Dermatologia

Target Recruit Count: 80

Registration Number: NCT03096457

Locations: 🇧🇴
Hospital Dermatologico de Jorochito, Jorochito, SC, Bolivia
🇧🇴
Hospital Local Palos Blancos, Palos Blancos, La Paz, Bolivia

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

Phase 3

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: WR 279,396
Drug: Paromomycin

First Posted Date: 2013-02-13

Last Posted Date: 2018-02-14

Lead Sponsor: U.S. Army Medical Research and Development Command

Target Recruit Count: 399

Registration Number: NCT01790659

Locations: 🇵🇦
Instituto Conmemorativo Gorgas de Estudios de la Salud,, Panama City, Panama

The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit

Not Applicable

Conditions: Concentration-Time Profiles in Stomach & Intestine.

Interventions: Drug: Paromomycin Sulfate w/ loperamide HCl
Drug: Paromomycin Sulfate Fasted State
Drug: Paromomycin Sulfate Fed State
Drug: Paromomycin Sulfate w/ domperidone

First Posted Date: 2013-01-31

Last Posted Date: 2014-01-29

Lead Sponsor: KU Leuven

Target Recruit Count: 10

Registration Number: NCT01780909

Locations: 🇧🇪
Gasthuisberg, Leuven, BE, Belgium

Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

Conditions: Leishmaniasis, Cutaneous

First Posted Date: 2012-07-17

Last Posted Date: 2020-05-15

Lead Sponsor: U.S. Army Medical Research and Development Command

Registration Number: NCT01641796

Locations: 🇺🇸
Military Treatment Facilities, Multiple Locations, Maryland, United States
🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy